The race to control pain: more participants, more targets.
Chizh
B A
BA
Department of Pharmacology II, Grünenthal GmbH Research and Development, Zieglerstrasse 6, D-52078 Aachen, Germany. BorisChizh@aol.com
Dickenson
A H
AH
Wnendt
S
S
D000085:Acetates / Q000627:therapeutic use; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D018722:Nicotinic Agonists / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy*; D011955:Receptors, Drug / Q000187:drug effects; D015222:Sodium Channels / Q000187:drug effects; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists; D018722:Nicotinic Agonists; D011955:Receptors, Drug; D015222:Sodium Channels; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin